SCHEDULE: Vanguard Discloses 5.02% Stake in Integra LifeSciences

Vanguard Portfolio Management has reported beneficial ownership of 5.02% of Integra LifeSciences Holdings Corp. common stock as of June 30, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, now beneficially owns 3,912,816 shares of Integra LifeSciences Holdings Corp. common stock.
• This holding represents 5.02% of the class of securities.
• The filing indicates that Vanguard Portfolio Management has sole dispositive power over these shares and sole voting power over 169,723 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating institutional confidence without providing specific operational or financial performance data.

Positives

• Vanguard's increased stake suggests confidence in Integra LifeSciences' long-term prospects.
• The filing confirms a significant institutional investor's commitment to the company.

Risks

• Potential for increased market influence by Vanguard, which could impact future corporate decisions.
• The concentration of ownership could lead to shifts in stock price based on Vanguard's trading activities.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Integra LifeSciences. It solely reports Vanguard's ownership stake.

Industry Context

StockSavvy.ai notes that a significant stake disclosure by a major asset manager like Vanguard in a medical technology company like Integra LifeSciences often signals a belief in the company's growth trajectory and market position within the competitive healthcare sector.

Stakeholder Impact

• Shareholders may see increased trading volume and potential price fluctuations due to Vanguard's significant holding.
• Management of Integra LifeSciences may consider Vanguard's perspective in strategic decision-making.

Next Steps

• Monitor future filings from Vanguard for any changes in ownership.
• Observe Integra LifeSciences' performance and strategic announcements for context regarding Vanguard's investment.

Key Dates

Recommendation

The filing indicates a significant institutional holding but does not provide new operational or financial performance data for Integra LifeSciences. This suggests a stable outlook based on existing information, warranting a 'hold' recommendation until further performance updates are available.

Keywords

Integra LifeSciences, Vanguard, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare, Medical Devices, Investment Management